Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving transferase
Reexamination Certificate
2011-06-14
2011-06-14
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving transferase
C435S007100
Reexamination Certificate
active
07960133
ABSTRACT:
The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases. In certain embodiments, such methods and compositions involve a COMT inhibitor.
REFERENCES:
patent: 5633371 (1997-05-01), Bernauer et al.
patent: 6258827 (2001-07-01), Chenard et al.
patent: 2002/0006653 (2002-01-01), Meyers et al.
patent: 2003/0100476 (2003-05-01), Weinberger et al.
patent: 2003/0190381 (2003-10-01), Bland et al.
patent: 2003/0199472 (2003-10-01), Al-Hendy et al.
Huber A., et al. Ten Estrogen Related Polymorphisms and Endometriosis. Obstetrics & Gynecology 106(5 Pt. 1)1025-1031, Nov. 2005.
Lu, H. et al. Enzymology of Methylation of Tea Catechins and Inhibition of COMT . . . Drug Metabolism and Metabolism 31(5)572-579, 2005.
Garner E. et al. Polymorphisms of the Estrogen Metabolizing Genes CYP17 and Catechol-O-Methyltransferase and Risk of Epithelial Ovarian Cancer. Cancer Research 3058-3062, Jun. 1, 2002.
Vangala V. et al. Synthesis of Catechol Estrogens by Human Uterus and Leiomyoma. Steroids 37(2)195-203, Feb. 1981.
Al-Hendy and Luxon et al., “Differential RNA Microarray Analysis of Normal Human Myometrium, Smal and Large Leiomyoma,”J. Soc. Gynecol. Investig., 9(1):307, 2002 (Abstract No. 744).
Al-Hendy and Salama, “Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups,”J. Soc. Gynecol. Investig., 13:136-144, 2006.
Al-Hendy and Salama, “Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans,”Fertil. Steril., 86:686-693, 2006.
Al-Hendy and Salama, “Gene therapy and uterine leiomyoma: a review,”Human Reproduction Update, 12:385-400, 2006.
Andersen et al., “Leiomyoma Primary Cultures Have Elevated Transcriptional Response to Estrogen Compared with Autologous Myomtrial Cultures,”J. Soc. Gynecol. Investig., 2:542-551, 1995.
Balloch, “The relative frequency of fibroid processes in the dark-skinned races,”Medical News, LXIV:29-35, 1894.
Barchiesi et al., “2-Methoxyestradiol inhibits human aortic smooth muscle cell growth via double blockade of cell-cycle and modulation of cell-cycle regulators,”Hypertension, 42:415, 2003 (P57, abstract).
Barchiesi et al., “Methoxyestradiols Mediate Estradiol-Induced Antimitogenesis in Human Aoritc SMCs,”Hypertension, 39:874-879, 2002.
Bertelli et al., “Antiplatelet Activity of CIS-Resveratrol,”Drugs Explt. Clin. Res., XXII:61-63, 1996.
Bonifacio et al., “Catechol-O-methyltransferase and its inhibitors in Parkinson's disease,”CNS Drug Reviews, 13:352-379, 2007.
Brandon et al., “Estrogen Receptor Gene Expression in Human Uterine Leiomyomata,”J. Clin. Endocrinol. Metab., 80:1876-1881, 1995.
Chappell et al., “Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial,”LANCET, 354:810-816, 1999.
Chegini et al., “Gene Expression Profile of Leiomyoma and Myometrium and the Effect of Gonadotropin Releasing Hormone Analogue Therapy,”J. Soc. Gynecol. Investig., 10:161-171, 2003.
Cramer and Patel, “The frequency of uterine leiomyomas,”Am. J. Clin. Pathol., 94(4):435-8, 1990.
Dawood et al., “Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol,”Fertil. Steril., 52:21-26, 1989.
Deligdish and Loewenthal, “Endometrial changes associated with myomata of the uterus,”J. Clin. Pathol., 23:676-680, 1970.
Dubey et al., “Clinically Used Estrogens Differentially Inhibit Human Aortic Smooth Muscle Cell Growth and Mitogen-Activated Protein Kinase Activity,”Arterioscler. Thromb. Vasc. Biol., 20:964-972, 2000.
Frisch et al., “Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients,”Mol. Psychiatry, 6:243-245, 2001.
Fuchs-Young et al., “Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators,”Mol. Carcinog., 17:151-159, 1996.
Goodman et al., “Case-Control Study of Ovarian Cancer and Polymorphisms in Genes Inolved in Catecholestrogen Formation and Metabolism,”Cancer Epidemiology Biomarkers&Prevention, 10:209-216, 2001.
Goodman et al., “COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk,”Carcinogenesis, 22:1661-1665, 2001.
Gordon et al., “Amenorrhea and bone health in adolescents and young women,”Curr. Opin. Obstet. Gynecol., 15(5):377-384, 2003.
Gutpa et al., “Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells,”J. Steroid Biochem. Mol. Biol., 67(5-6):413-419, 1998.
Haram et al., “Preterm delivery: an overview,”Acta. Obstet. Gynecol. Scand., 82:687-704, 2003.
Howe et al., “Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines,”Am. J. Pathol., 146:1568-1579, 1995.
Hsieh et al., “Estrogen receptor thymine-adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma,”Fertil. Steril., 79:96-99, 2003.
Huang et al., “Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility,”Cancer Res., 59:4870-4875, 1999.
Kitawaki et al., “Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata,”Hum. Reprod., 16:51-55, 2001.
Kjerulff et al., “Hysterectomy and race,”Obstet. Gynecol., 82:757-764, 1993.
Kola et al., “Co-administration of ascorbic acid with cyclophosphamide (CPA) to pregnant mice inhibits the clastogenic activity of CPA in preimplantation murine blastocysts,”Mutagenesis, 4:297-301, 1989.
Lachman et al., “Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders,”Pharmacogenetics, 6:243-250, 1996.
Lal et al., Combined Antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats,Diabetes, 49:1381-1389, 2000.
Lavigne et al., “An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer,”Cancer Research, 57:5493-5497, 1997.
Lethaby et al., “Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids (Cochrane Review),”The Cochrane Library, Oxford: Update Software Ltd., Issue 1, 2003 (Abstract).
Linde, In:Operative Gynecology, Rock and Thompson (Eds.), Philadelphia: Lippincott-Raven; 732-770, 1997.
Marshall et al., “Variation in the incidence of uterine leiomyoma among premenopausal women by age and race,”Obstet. Gynecol., 90:967-973, 1997.
Massart et al., “Genotype distribution of estrogen receptor-alpha gene polymorphisms in Italian women with surgical uterine leiomyomas,”Fertil. Steril., 75:567-570, 2001.
Matsuo et al., “Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone,”J Clin Endocrinol Metab., 82:293-299, 1997.
McLeod et al., “Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans,”J. Pharmacol. Exp. Ther., 270:26-29, 1994.
Mitrunen et al., “Polymorphic catechol-O-methyltransferase gene and breast cancer risk,ȁ
Fulbright & Jaworski L.L.P.
Gitomer Ralph
The Board of Regents of the University of Texas System
LandOfFree
Methods of diagnosing leiomyoma by measuring... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing leiomyoma by measuring..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing leiomyoma by measuring... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676278